Search research articles
Contact Us
Filters
Showing results (201-210 of 327) with videos related to
Page
of 33
Sort By:
Journal of Translational Medicine
|
December 11, 2012
The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon
Pierre L Triozzi, Susan Achberger, Wayne Aldrich, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
January 18, 2011
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial
Ernest C Borden, Barbara Jacobs, Emese Hollovary, et al.
Journal of Interferon Research
|
September 1, 1989
Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser
A P Larocca, S C Leung, S G Marcus, et al.
Journal of Biological Response Modifiers
|
February 1, 1990
Biological and clinical effects of the oral immunomodulator 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy
G J Litton, R Hong, S E Grossberg, et al.
Oncogene
|
January 18, 2012
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth
K Zhang, P Wong, L Zhang, et al.
American Journal of Clinical Oncology
|
February 8, 2006
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma
Gary Von Burton, Cathy Rankin, Mark M Zalupski, et al.
The Journal of Biological Chemistry
|
July 31, 2004
Reverse signaling through membrane-bound interleukin-15
Vadim Budagian, Elena Bulanova, Zane Orinska, et al.
The Journal of Clinical Investigation
|
September 8, 2007
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells
Venugopalan Cheriyath, Keith B Glaser, Jeffrey F Waring, et al.
American Journal of Clinical Oncology
|
October 22, 1998
Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group
M A Rosenthal, M Green, P Wiernik, et al.
Oncology (Williston Park, N.Y.)
|
June 26, 2018
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
Ericson Stoen, Peter Kabos, Kelly C Borden, et al.
Page
of 33
Search research articles
Search
Showing results (201-210 of 327) with videos related to
Sort By:
Page
of 33
Journal of Translational Medicine
|
December 11, 2012
The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon
Pierre L Triozzi, Susan Achberger, Wayne Aldrich, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
January 18, 2011
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial
Ernest C Borden, Barbara Jacobs, Emese Hollovary, et al.
Journal of Interferon Research
|
September 1, 1989
Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser
A P Larocca, S C Leung, S G Marcus, et al.
Journal of Biological Response Modifiers
|
February 1, 1990
Biological and clinical effects of the oral immunomodulator 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy
G J Litton, R Hong, S E Grossberg, et al.
Oncogene
|
January 18, 2012
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth
K Zhang, P Wong, L Zhang, et al.
American Journal of Clinical Oncology
|
February 8, 2006
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma
Gary Von Burton, Cathy Rankin, Mark M Zalupski, et al.
The Journal of Biological Chemistry
|
July 31, 2004
Reverse signaling through membrane-bound interleukin-15
Vadim Budagian, Elena Bulanova, Zane Orinska, et al.
The Journal of Clinical Investigation
|
September 8, 2007
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells
Venugopalan Cheriyath, Keith B Glaser, Jeffrey F Waring, et al.
American Journal of Clinical Oncology
|
October 22, 1998
Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group
M A Rosenthal, M Green, P Wiernik, et al.
Oncology (Williston Park, N.Y.)
|
June 26, 2018
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
Ericson Stoen, Peter Kabos, Kelly C Borden, et al.
Page
of 33